Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.55 USD
Change Today -0.04 / -0.53%
Volume 149.7K
DSCI On Other Exchanges
As of 5:20 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

derma sciences inc (DSCI) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/2/14 - $12.02
52 Week Low
03/11/15 - $7.27
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DERMA SCIENCES INC (DSCI)

Related News

No related news articles were found.

derma sciences inc (DSCI) Related Businessweek News

No Related Businessweek News Found

derma sciences inc (DSCI) Details

Derma Sciences, Inc. operates as a tissue regeneration company in the wound care market. Its Advanced Wound Care segment offers MEDIHONEY dressings for managing non-chronic and hard-to-heal wounds, including chronic ulcers, burns, and post-operative wounds; TCC-EZ system for patients with diabetic foot ulcers; AMNIOEXCEL for tissue repair, reconstruction, and replacement; and AMNIOMATRIX that is used as a wound covering in the treatment of localized tissue defects. This segment also provides XTRASORB dressings, which convert fluid within the dressings to a gel and lock the exudates into the dressings; BIOGUARD dressings for prophylactic use in the prevention of hospital or community acquired infections through wound sites; ALGICELL AG antimicrobial dressings; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and DERMAGRAN products. The company’s Traditional Wound Care segment offers gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages, and other compression devices; adhesive bandages and related first aid products; private-label wound care products; wound closure strips, nasal tube fasteners, and catheter fasteners; and general purpose and specialized skin care products. Its Pharmaceutical Wound Care segment develops DSC127, an angiotensin analog that is in Phase III clinical trials for the treatment of diabetic foot ulcers, and preclinical testing for scar reduction. The company sells its products to various health care providers, including wound care centers, extended care facilities, acute care facilities, home health care agencies, physicians’ offices, nursing homes, hospitals, and clinics through direct sales and manufacturers’ representatives, independent distributors, and retail channels in the United States, Canada, and the United Kingdom. Derma Sciences, Inc. was founded in 1984 and is headquartered in Princeton, New Jersey.

299 Employees
Last Reported Date: 03/11/15
Founded in 1984

derma sciences inc (DSCI) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $530.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $270.0K
Executive Vice President of Operations and Ge...
Total Annual Compensation: $244.4K
Group President of Advanced Wound Care and Ph...
Total Annual Compensation: $320.0K
Group President of Traditional Wound Care and...
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2014.

derma sciences inc (DSCI) Key Developments

Derma Sciences Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Re-Affirms Earnings Guidance for 2015

Derma Sciences Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. The company's net sales for the fourth quarter of 2014 were $22.9 million, compared with $20.7 million for the fourth quarter of 2013, an increase of 10.5%. This included AWC product sales of $11.5 million, up 21.6% from $9.4 million in the prior-year quarter. Growth in AWC product sales was led by MEDIHONEY and TCC-EZ. The net loss for the fourth quarter of 2014 was $9.6 million, or $0.37 per share, compared with a net loss for the fourth quarter of 2013 of $5.4 million, or $0.31 per share. The increase in net loss was principally due to higher R&D expenses. Loss before income taxes was $9,459,714 against $4,971,757 a year ago. Operating loss was $9,533,646 against $5,068,834 a year ago. The company's net sales for 2014 were $83.7 million, up 5.1% from $79.7 million for 2013. AWC product sales were $38.1 million, up 12.3% compared with $33.9 million in 2013. TWC product sales were $45.6 million, down slightly from $45.8 million in 2013. The company reported a net loss for 2014 of $39.8 million, or $1.62 per share, compared with a net loss for 2013 of $24.0 million, or $1.40 per share. Loss before income taxes was $39,922,603 against $23,803,942 a year ago. Operating loss was $40,104,146 against $23,989,682 a year ago. The company affirmed the earnings guidance provided in January for 2015 net sales to be approximately $88.1 million, representing growth of 5.3% compared with 2014 net sales. Sales of AWC products are expected to be $43.8 million, up 15.0% over 2014. TWC products are expected to decline 2.9% to $44.3 million, reflecting the loss of a significant customer in 2015. Net sales are expected to increase as the year progresses, yet quarterly sales will be impacted by ordering patterns and delivery dates, particularly in the TWC business.

Derma Sciences, Inc. Names John Caminis as Chief Medical Officer

Derma Sciences Inc. announced the appointment of John Caminis, M.D. to the newly created position of chief medical officer. Dr. Caminis is a seasoned pharmaceutical physician with particular expertise in clinical drug development, and will report to Edward J. Quilty, the company’s chairman and CEO. Dr. Caminis has a wide range of experience in managing the clinical trial process for a multitude of therapeutic indications. Since 2011 he served as senior medical director in the immunology, and later in the bone patient value unit at UCB. Prior to UCB he was vice president, clinical development at Warner Chilcott (now Actavis). At Warner Chilcott he planned, designed, developed and oversaw clinical development programs in therapeutic areas such as bone metabolism, urology, dermatology and infectious disease. Earlier in his career Dr. Caminis had roles of increasing responsibility in clinical development and medical affairs programs at small as well as large companies like NPS Pharmaceutical, Novartis Pharmaceuticals and Roche Laboratories. While at NPS, he had a pivotal role in the execution and development of key assets for patients with rare diseases.

Derma Sciences Inc. to Report Q4, 2014 Results on Mar 12, 2015

Derma Sciences Inc. announced that they will report Q4, 2014 results on Mar 12, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSCI:US $7.55 USD -0.04

DSCI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliqua BioMedical Inc $4.73 USD +0.06
BioLargo Inc $0.29 USD -0.032
Integra LifeSciences Holdings Corp $64.62 USD -0.26
SANUWAVE Health Inc $0.12 USD -0.025
Smith & Nephew PLC 1,120 GBp +6.00
View Industry Companies

Industry Analysis


Industry Average

Valuation DSCI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DERMA SCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at